June 28, 2019
The article details the collaboration between PerkinElmer and FDNA to enhance rare disease diagnosis through the integration of genomic services and phenotyping technology. PerkinElmer brings its extensive genomic testing capabilities, while FDNA contributes its advanced AI-driven facial recognition technology. This partnership aims to create a comprehensive diagnostic platform that combines genetic and phenotypic data, significantly improving diagnostic accuracy and speed. By leveraging these complementary technologies, the collaboration seeks to provide more precise and actionable insights for clinicians, ultimately facilitating earlier and more accurate identification of rare genetic disorders. This integrated approach marks a significant advancement in personalized medicine and rare disease management.
